Search results

Biotech is the key growth area for pharma and life sciences, and Swiss-based biotech companies play a major role across the entire development cycle, from their share of the pipeline, to clinical trial activity, to the emerging commercialization of new molecules. Switzerland’s ability to drive and nurture innovation is continuing to expand.

In 2022, Pfizer acquired Arena Pharmaceuticals, a San Diego-based clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Amit Munshi, former President and Chief Executive Officer, talks with Switzerland Global Enterprise about why Arena Pharmaceuticals’ Swiss hub was not only crucial to the company’s success, but how other gl

Global advances in biotechnology and personalized medicine pose a challenge to regulatory authorities. Patients expect to benefit as quickly as possible from innovative and effective therapeutic products and treatments, but these must be safe and of high quality.

In a challenging global stock market environment, companies from the life sciences sector listed on SIX Swiss Exchange continue to benefit from a robust, resilient capital market with comparatively low market volatilities.

The Swiss biotech industry is innovative, internationally connected, and versatile. It owes its strength to its ability to innovate in collaboration with global partners and evolve with changing market dynamics.

Industrial biotechnologies developed and applied by Swiss companies have already demonstrated their potential to lower the environmental footprint of the industry by reducing greenhouse gas emissions and the consumption of limited biological resources. In the healthcare sector, biotechnology plays a crucial role in the manufacture of active ingredients and the development of innovative therapies a

The intrinsic advantages of biotechnology are indisputable. The combination of exponential growth and the precision of biochemical reactions offers the promise of truly sustainable production.

The world as a whole – and specifically the healthcare system – faces tough challenges, including the aftermath of the recent pandemic and rising healthcare costs. Collaborations between academic institutions, research organizations, and industry to propose, promote and implement innovations will help the biotechnology sector deliver solutions to existing and emerging issues. As a network of r

Inventors who are resident in Switzerland contribute disproportionately to the global biotech patent portfolio, in terms of both quantity and quality. The claim that Swiss biotech inventions provide global solutions is justified by their high impact, combining technological relevance with a broad coverage of global markets. Three out of four biotech patent applications listing Swiss inventors are

Virtually all of today’s innovation stands on the shoulders of great scientists. Some researchers have explored an apparently inconsequential detail of a bizarre phenomenon that nobody knew about – until everybody knew about it. They carried out basic, curiosity-driven research, pushing their luck and hoping for a serendipitous discovery.

The life sciences sector (pharmaceuticals, vitamins and diagnostics) represents the largest export industry of Switzerland. In 2022, it accounted for 39% of total Swiss exports and added a record CHF 109.6 billion (+0.6% over 2021) to the foreign export trade.

In 2022, the global biotech sector, like many other sectors, was impacted by geopolitical challenges, which dried up or reduced some sources of funding. However, with the impact of the pandemic diminishing (thanks to the new mRNA vaccination capabilities) the “new world” also brought welcome relief to the healthcare sector around the globe.

Some major achievements of Swiss biotech innovation…